# Alopecia Areata

Confirm nonscarring alopecia areata clinically and with trichoscopy, exclude infectious or inflammatory mimics when indicated, quantify scalp loss with SALT, and match localized disease to intralesional corticosteroids versus FDA-approved oral JAK inhibition for severe disease.

**Clinical question:** How should physicians diagnose, stage, and select treatment for localized versus severe alopecia areata?

Updated: 2026-09-15T23:13:06.607946+00:00

## What matters in practice
- Use scalp examination and trichoscopy to establish a nonscarring alopecia pattern; yellow dots are a characteristic trichoscopic finding in alopecia areata. [1]
- Record baseline Severity of Alopecia Tool (SALT) score to quantify scalp involvement and assess response longitudinally. [13]
- For active localized disease, intralesional triamcinolone acetonide is a first-line option; published consensus dosing is 2.5-10 mg/mL, with 10-20 mg maximum per session every 2-6 weeks. [18]
- Consider FDA-approved oral JAK inhibition for severe disease: baricitinib for adults and ritlecitinib for patients aged 12 years or older. [16][18]
- Laboratory testing should be targeted to diagnostic mimics, clinical suspicion of autoimmune comorbidity, and baseline or follow-up requirements for systemic treatment rather than performed reflexively in every patient. [9][11]

## Confirm alopecia areata and identify diagnoses that change management

Prioritize exclusion of scarring alopecia and infectious mimics before immunosuppression.

Document distribution, extent, activity, eyebrow/eyelash and body-hair involvement, nail findings, and scalp symptoms. Alopecia areata is a nonscarring autoimmune alopecia; preservation of follicular openings supports this branch, whereas inflammatory follicular lesions, scale, or a clinically unexpected course should prompt reconsideration of infection, lupus erythematosus, lichen planopilaris, or another cicatricial alopecia. [7][16]

Perform trichoscopy at the alopecic patch and active edge when the clinical diagnosis is uncertain. Yellow dots are characteristic of alopecia areata. Trichoscopy can also direct biopsy selection when lesions are follicular, atypical, or fail expected treatment, although overlapping dermoscopic findings prevent reliance on a single sign to exclude other scalp disorders. [1][6]

Biopsy an active, representative lesion when scarring alopecia, cutaneous lupus, lichen planopilaris, folliculotropic mycosis fungoides, or another mimic remains plausible after examination and trichoscopy. Dermoscopy-guided biopsy is particularly useful for follicular lesions behaving unexpectedly or not responding to treatment. [6][24]
- Evaluate for tinea capitis, secondary syphilis, and lupus when morphology, symptoms, exposure history, or systemic findings suggest these mimics; each changes treatment away from alopecia-directed immunotherapy. [9]
- Do not interpret nonspecific vitamin, iron, or zinc abnormalities as proof of alopecia areata causation; expert testing practices vary substantially for potentially contributory abnormalities. [9][11]

*Diagnostic branch points in patchy scalp alopecia. [1][6][9][24]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Nonscarring patch with yellow dots on trichoscopy | Supports alopecia areata. [1] | Stage extent with SALT and select treatment by disease burden and patient goals. [13] |
| Scale, inflammatory follicular lesions, or clinical concern for infection | Consider tinea capitis or other infectious follicular disease. [6][9] | Pursue infection-directed evaluation before systemic immunomodulation. [9] |
| Loss of follicular ostia, perifollicular inflammatory change, or atypical persistent plaques | Raises concern for cicatricial alopecia, lupus, lichen planopilaris, or folliculotropic mycosis fungoides. [6][24] | Use trichoscopy to choose an active biopsy site. [6] |
| Unexpected course or no meaningful response to the presumed diagnosis | Diagnostic reassessment is required because trichoscopic patterns overlap among follicular diseases. [6] | Repeat examination and obtain a dermoscopy-guided biopsy when appropriate. [6] |

## Quantify severity and recognize patterns associated with greater treatment need

Use a reproducible baseline measure before treating and at follow-up.

Calculate and record the Severity of Alopecia Tool score at baseline; SALT has been validated for alopecia areata trials and routine practice. Use serial SALT measurements rather than an unstructured impression of density to determine whether localized therapy is adequate or whether severe disease warrants systemic discussion. [13]

Classify complete scalp hair loss clinically as alopecia totalis and complete scalp and body hair loss as alopecia universalis. These phenotypes begin with SALT 100 and are represented among patients treated with ritlecitinib in long-term studies; severe baseline burden should prompt early discussion of systemic options rather than prolonged cycles of painful focal injections. [12]

Ask directly about functional and psychosocial impact, including anxiety, depression symptoms, concealment burden, and occupational or social impairment. Alopecia areata is associated with lower quality of life and psychiatric comorbidity, and structured assessment can change the urgency of treatment escalation and behavioral-health referral. [7][14][21]
- Photograph scalp, brows, and lashes at baseline under consistent conditions to complement serial SALT assessment. [13]
- Reassess active disease and regrowth after each intralesional treatment cycle; historical reports describe regrowth within 4-6 weeks, but continued treatment for 3-4 months was needed in some patients. [3]
- Discuss that long-standing extensive disease may have a lower likelihood of satisfactory response than mild patchy disease; observational long-term data associate severe totalis/universalis patterns with poorer outcomes. [15]

*Severity-directed treatment framing. [12][13][18]*

| Clinical pattern | Measurement | Treatment implication |
| --- | --- | --- |
| Limited patchy scalp involvement | Baseline and serial SALT score; lesion photographs. [13] | Localized intralesional triamcinolone is a first-line treatment option for active disease. [18] |
| Extensive scalp loss | Serial SALT score to quantify burden and response. [13] | Discuss systemic treatment options, including FDA-approved JAK inhibitors when disease is severe. [16][18] |
| Alopecia totalis or universalis | SALT 100 at baseline in the clinical trial classification. [12] | Prioritize counseling about lower response certainty and systemic therapy tradeoffs; focal injections alone are often impractical for large affected areas. [2][12] |

## Use targeted laboratory testing rather than an undifferentiated alopecia panel

Testing should answer a specific diagnostic, comorbidity, or treatment-safety question.

Order testing when it is triggered by a plausible mimic, symptoms or signs of an associated autoimmune disease, or intended systemic treatment. Expert consensus addresses laboratory evaluation in alopecia areata, but real-world testing remains variable and often extends to thyroid disease, coeliac disease, pernicious anemia, iron, zinc, and vitamin D assessment. [9][11]

When secondary syphilis, tinea capitis, or lupus is clinically plausible, direct testing toward that alternative diagnosis rather than labeling the patient with alopecia areata on morphology alone. A positive mimic workup changes treatment selection and may preclude or defer immunosuppressive therapy. [9]

Before prescribing a systemic JAK inhibitor, obtain the baseline and ongoing safety evaluation required for that drug and follow current U.S. product labeling. The literature identifies screening and monitoring for contraindications and adverse effects of JAK inhibitors as a distinct indication for laboratory testing in alopecia areata. [9]
- Use autoimmune testing selectively when history, examination, or symptoms suggest thyroid disease, coeliac disease, pernicious anemia, vitiligo, lupus, or another autoimmune condition. [9][16]
- Do not allow normal laboratory findings to override a convincing clinical and trichoscopic diagnosis; laboratory testing is principally used for mimics, associations, contributory factors, and systemic-therapy safety. [9][11]

*Laboratory testing should be linked to the clinical question. [9][11]*

| Clinical trigger | Testing purpose | Result changes |
| --- | --- | --- |
| Morphology or history suggests tinea capitis, secondary syphilis, or lupus | Evaluate an infectious or inflammatory mimic. [9] | Treat the alternative diagnosis rather than escalating alopecia areata therapy. [9] |
| Symptoms or signs suggest autoimmune comorbidity | Assess thyroid disease, coeliac disease, pernicious anemia, or another suspected autoimmune condition. [9] | Initiate disease-specific evaluation or co-management if confirmed. [9] |
| Considering or receiving a JAK inhibitor | Screen and monitor for systemic-treatment contraindications or adverse effects. [9] | Determine eligibility and whether treatment can be continued safely. [9] |

## Treat active limited alopecia areata with intralesional corticosteroids

Use focal injection therapy when affected area and patient tolerance make local treatment practical.

For active patchy alopecia areata, intralesional triamcinolone acetonide is regarded as first-line treatment. Use concentrations of 2.5-10 mg/mL, limit total dose to 10-20 mg per session, and repeat at 2-6-week intervals. The cited consensus identifies 10 mg/mL on the scalp as producing an optimal response with acceptable adverse reactions, but concentration and cumulative exposure should be individualized to site and atrophy risk. [18]

Assess for regrowth and local toxicity at each visit. Pain, bleeding, headache, systemic absorption, dyschromia, and reversible local cutaneous atrophy are recognized adverse effects; repeated injections may also produce transient rather than durable responses. [2][18]

Stop a nonresponsive injection strategy after 6 months and reassess the diagnosis, disease extent, treatment feasibility, and systemic options. This threshold also prevents indefinite exposure to injection pain and local atrophy in a patient who is unlikely to benefit from continued focal treatment. [18]
- Avoid using intralesional treatment as the sole strategy for very large areas when repeated injections become painful or impractical. [2]
- Topical corticosteroids may be used in practice, but evidence summarized in an evidence-based review characterizes topical and intralesional corticosteroids as moderately effective short-term treatments for patchy disease. [17]
- Explain that topical corticosteroids and topical macrolide immunomodulators may have limited efficacy because of insufficient penetration to the hair bulb. [2]

*Intralesional triamcinolone treatment parameters for active alopecia areata. [18]*

| Parameter | Practical specification | Decision point |
| --- | --- | --- |
| Agent | Triamcinolone acetonide. [18] | Use for active localized alopecia areata. [18] |
| Concentration | 2.5-10 mg/mL; 10 mg/mL is reported as optimal for scalp response with acceptable adverse reactions. [18] | Use lower exposure where local atrophy risk is a concern. [18] |
| Maximum session dose | 10-20 mg. [18] | Do not exceed the cited session range. [18] |
| Interval | Every 2-6 weeks. [18] | Assess regrowth and adverse effects before reinjection. [18] |
| Stopping rule | Discontinue if no improvement within 6 months. [18] | Reassess diagnosis and escalate or change treatment strategy. [18] |

## Use FDA-approved JAK inhibitors when severe alopecia areata warrants systemic treatment

Select systemic therapy by age, severity, patient priorities, and safety eligibility.

For adults with severe alopecia areata, baricitinib is FDA approved. In the BRAVE-AA1 and BRAVE-AA2 phase 3 trials, SALT scores of 20 or less at week 52 occurred in 40.9% and 21.2% of patients receiving 4 mg and 2 mg, respectively, in BRAVE-AA1 and in 36.8% and 24.4%, respectively, in BRAVE-AA2. These results support expectation-setting: meaningful scalp regrowth occurs in a subset, not all treated patients. [7][16]

For severe alopecia areata in patients aged 12 years or older, ritlecitinib is an FDA-approved option. In ALLEGRO, 23% receiving ritlecitinib 50 mg achieved SALT 20 or less at week 24 versus 1.5% with placebo; continued daily 50-mg treatment was associated with progressive improvement in SALT distribution through 24 months. [7][12][18]

Use current U.S. prescribing information for agent-specific contraindications, pretreatment screening, dose modification, and adverse-effect monitoring. Do not substitute off-label JAK inhibitors or conventional systemic immunosuppressants for an approved agent without documenting the rationale, because evidence quality and optimal dosing for agents such as methotrexate and sulfasalazine remain limited. [9][15]
- Choose baricitinib only for adults with severe disease; its FDA approval for severe alopecia areata dates to 2022. [16]
- Ritlecitinib provides an approved systemic option beginning at age 12 years for severe disease. [7][18]
- Frame response using serial SALT rather than photographs alone; the key trial outcome was SALT 20 or less. [7][12][13]
- Avoid relying on systemic cyclosporine as a routine equivalent to approved JAK therapy; small case series reported cosmetically acceptable results in only 25%-50% and systemic toxicity constrains use. [2]

*FDA-approved systemic JAK inhibitor evidence for severe alopecia areata. [7][12][16][18]*

| Agent | Eligible population | Efficacy benchmark | Clinical use |
| --- | --- | --- | --- |
| Baricitinib | Adults with severe alopecia areata. [16][18] | SALT ≤20 at week 52: 40.9% with 4 mg and 21.2% with 2 mg in BRAVE-AA1; 36.8% and 24.4%, respectively, in BRAVE-AA2. [7] | Discuss expected benefit, safety screening, monitoring, and need for serial SALT assessment. [7][9][13] |
| Ritlecitinib | Patients aged ≥12 years with severe alopecia areata. [7][18] | Ritlecitinib 50 mg: SALT ≤20 at week 24 in 23% versus 1.5% with placebo in ALLEGRO. [7] | Use daily 50 mg as studied; follow current U.S. labeling for safety management. [12][9] |

## Monitor response, toxicity, and diagnostic fidelity

Follow-up should have a predefined measurement and an escalation trigger.

At each follow-up, repeat SALT scoring, compare standardized photographs, inspect for active new patches and regrowth, and document local adverse effects when injections are used. For systemic therapy, incorporate the treatment-specific safety monitoring required by current labeling alongside clinical response assessment. [9][13][18]

Escalate from local to systemic discussion when disease is extensive, totalis/universalis is present, injections are impractical, patient burden is high, or there is no improvement after 6 months of intralesional therapy. Re-biopsy rather than merely escalating immunosuppression if the morphology becomes inflammatory, follicular, scarring, or otherwise discordant with alopecia areata. [6][18]

Include mental-health screening and referral when distress, anxiety, depression symptoms, or impaired function is identified. Psychiatric comorbidity and reduced quality of life are documented in alopecia areata and should be managed as treatment-relevant disease burden rather than an incidental reaction to cosmetic change. [7][14][21]
- Local injection toxicity: look specifically for cutaneous atrophy and dyschromia before reinjection. [18]
- Systemic-treatment monitoring: follow the selected JAK inhibitor's current U.S. labeling and laboratory safety requirements. [9]
- Diagnostic failure trigger: unexpected lesions or failure to respond should prompt trichoscopy-guided biopsy consideration. [6]

*Follow-up actions by treatment pathway. [6][9][13][18]*

| Pathway | Monitor | Escalate or change course when |
| --- | --- | --- |
| Intralesional triamcinolone | SALT, regrowth, pain, bleeding, dyschromia, and local atrophy at treatment visits. [13][18] | No improvement by 6 months, clinically meaningful toxicity, or disease becomes too extensive for practical injection treatment. [18][2] |
| Oral JAK inhibitor | Serial SALT plus agent-specific safety testing and adverse effects per current labeling. [9][13] | Safety evaluation changes eligibility or response and patient priorities no longer justify ongoing systemic exposure. [9] |
| Atypical or refractory presentation | Clinical morphology and trichoscopic findings. [6] | Obtain a dermoscopy-guided biopsy when mimic or scarring process remains a concern. [6][24] |

## References
1. Reflectance Confocal Microscopy of the Yellow Dot Pattern in ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/426451
2. Alefacept for Alopecia Areata — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/401021
3. Alopecia Areata - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/DERM/articlepdf/554546/archderm_128_11_016.pdf
4. Selectivity, efficacy and safety of JAKinibs: new evidence for a still ... — ard.bmj.com — https://ard.bmj.com/content/83/2/139
5. Trichoscopy criteria for diagnosing female androgenic alopecia. — www.nature.com — https://www.nature.com/articles/npre.2008.1913.1.pdf
6. Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-021-90168-9
7. ‌Global burden of alopecia areata from 1990 to 2019 and emerging treatment trends analyzed through GBD 2019 and bibliometric data | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-07224-x
8. Alopecia areata | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/s41572-025-00664-9
9. COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists - O'Connor - 2025 - JEADV Clinical Practice - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/jvc2.70067
10. Trichoscopy pattern and evaluation of serum vitamin D status in alopecia areata - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1572100023002387
11. The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0190962220326141
12. SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata - Reguiai - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jdv.20698
13. Objective outcome measures: Collecting meaningful data on alopecia areata - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0190962217326142
14. Lifetime prevalence of psychiatric disorders in patients with alopecia areata - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/0010440X9190045E
15. Real-world evidence in alopecia areata treatment:... : Dermatologica Sinica — journals.lww.com — https://journals.lww.com/ders/fulltext/2026/01000/real_world_evidence_in_alopecia_areata_treatment_.3.aspx
16. Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report | Skin Health and Disease | Oxford Academic — academic.oup.com — https://academic.oup.com/skinhd/article/5/1/66/7972527
17. What is the most effective treatment for alopecia areata? - Ovid — journals.lww.com — https://journals.lww.com/ebp/fulltext/2015/05000/what_is_the_most_effective_treatment_for_alopecia.17.aspx
18. Taiwanese Dermatological Association consensus on... : Dermatologica Sinica — journals.lww.com — https://journals.lww.com/ders/_layouts/15/oaks.journals/downloadpdf.aspx?an=00701581-202501000-00004
19. A Comprehensive Overview on Alopecia Areata with Review on ... — journals.lww.com — https://journals.lww.com/ijd/_layouts/15/oaks.journals/downloadpdf.aspx?an=00076423-990000000-00329
20. Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12429261
21. Alopecia Areata: Pathogenesis, Diagnosis, and Therapies — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12010142
22. Interventions for alopecia areata — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13287352
23. Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13264305
24. [PDF] Dermoscopy in selected disorders of scarring alopecia — applications.emro.who.int — https://applications.emro.who.int/imemrf/J_Pak_Assoc_Dermatol/J_Pak_Assoc_Dermatol_2018_28_4_449_451.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.